Objective To investigate the cardiorenal protective effects of statins, and the pathophysiologic mechanism between cardiac insufficiency and renal insufficiency was also discussed. Methods Twenty-four Wistar rats were divided into three groups: blank control group (n=4), statins group(n=10), and isoproterenal(ISO) group(n=10). Rats in blank control group and ISO group received normal saline (2ml/d) by intragastric administration. Rats in statins group received rosuvastatin [4mg/(kg?d)] by intragastric administration. Two weeks later, rats in ISO group and statins group received isoproterenol injection twice [85 mg/(kg?d)] intraperitoneally, while rats in blank control group received normal saline (2ml/d). After 15 weeks, the heart function of the rats was evaluated by cardiac ultrasound; a series of blood detections on renin angiotensin aldosterone system (RAAS), antioxidase, and inflammation factors were performed; additionally, heart and kidney tissues were also examined histopathologically to analyze the organ damage. Results Compared with ISO group, rats in statins group exhibited a signi?cant improvement in heart function [LVEF: (73.18±7.89)% vs (58.58±6.41)%, P＜0.05] and reduction in serum AngⅡ level [(928.50±536.87) vs (1886.80±718.89) pg/ml, P＜0.05]. In addition, rats in statins group showed a decrease in serum malondialdehyde [(10.10±0.74) vs (12.36±2.11) nmol/ml, P=0.073], and interleukin-6 [(44.46±24.57) vs (76.31±20.79) ng/ml, P=0.058] levels compared with rats in ISO group, but not reaching statistical significance. Histopathological examination showed significant protective effect of rosuvastatin on heart and kidney. Conclusion Rosuvastatin could protect cardiac and renal structure and function in ISO-induced cardiac insufficiency rats, possibly through RAAS inhibition and anti-oxidation or anti-inflammation.